Regarding the evidence-based use of micronized progesterone

Authors

  • A. D. Makatsariya N.F. Filatov Clinical Institute of Children’s Health, Sechenov University, Russian Federation https://orcid.org/0000-0001-7415-4633
  • G. C. Di Renzo N.F. Filatov Clinical Institute of Children’s Health, Sechenov University, Moscow, Russia; Center for Prenatal and Reproductive Medicine, University of Perugia, Italy; International Federation of Gynecology and Obstetrics (FIGO), https://orcid.org/0000-0003-4467-240X
  • G. Rizzo N.F. Filatov Clinical Institute of Children’s Health, Sechenov University, Moscow, Russia; Tor Vergata University of Rome, Rome, Italy, https://orcid.org/0000-0002-5525-4353

DOI:

https://doi.org/10.18370/2309-4117.2020.55.105-108

Keywords:

gestagens, progesterone, dydrogesterone, habitual miscarriage, evidence base

Abstract

An issue of habitual miscarriage poses a high social importance especially during COVID-19 pandemic. Meanwhile, healthcare workers faced a mass media campaign against using micronized progesterone upon habitual miscarriage, which, as viewed by publication authors, displays signs of prejudiced data manipulation and may disorient practitioners.

Authors of published letter provide objective information on accumulated data regarding gestagens efficacy and safety. They invoke healthcare professionals to make decisions deserving independent primary source trust presented by original scientific papers published in peer-reviewed journals, clinical recommendations proposed by professional medical communities as well as treatment standards and protocols.

Author Biographies

A. D. Makatsariya, N.F. Filatov Clinical Institute of Children’s Health, Sechenov University

MD, professor, academician of RAS, head of the Department of Obstetrics and Gynecology;

Vice-president of the Russian Society of Obstetricians and Gynecologists

G. C. Di Renzo, N.F. Filatov Clinical Institute of Children’s Health, Sechenov University, Moscow, Russia; Center for Prenatal and Reproductive Medicine, University of Perugia, Italy; International Federation of Gynecology and Obstetrics (FIGO)

Professor, Department of Obstetrics and Gynecology;

Director;

Honorary Secretary General 

G. Rizzo, N.F. Filatov Clinical Institute of Children’s Health, Sechenov University, Moscow, Russia; Tor Vergata University of Rome, Rome, Italy

MD, professor, Department of Obstetrics and Gynecology

Downloads

Published

2020-11-30

How to Cite

Makatsariya, A. D., Di Renzo, G. C., & Rizzo, G. (2020). Regarding the evidence-based use of micronized progesterone. REPRODUCTIVE ENDOCRINOLOGY, (55), 105–108. https://doi.org/10.18370/2309-4117.2020.55.105-108

Issue

No. 55 (2020)

Section

Analytical review

License

Copyright (c) 2020 A. D. Makatsariya, G. C. Di Renzo, G. Rizzo

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

    1. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.